SCHEMBL4842323

SCHEMBL4842323

COc1cccc(CNCC(O)COc2ccc(-c3nc4cc(Br)cnc4[nH]3)cc2)c1

nearest known ligand 0.47

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.45
KMT2A Q03164 1/20 0.45
DNM1 Q05193 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4846277 0.93 KMT2A (0.42) ALDH1A1KMT2A
SCHEMBL4838763 0.89 MEN1 (0.42) KMT2A
SCHEMBL4844289 0.89 MEN1 (0.51) KMT2ADNM1
SCHEMBL4842045 0.86 ACHE (0.46) ALDH1A1KMT2A
SCHEMBL4834677 0.85 SCN8A (0.44) ALDH1A1KMT2A
SCHEMBL4845549 0.85 NPC1 (0.40)
SCHEMBL4843616 0.85
SCHEMBL4841328 0.84 KMT2A (0.47) KMT2A
Trifluoroacetic Acid SCHEMBL5258414 0.83 MEN1 (0.43) KMT2A
SCHEMBL4841793 0.83 MAPT (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1539759-B1 NOVEL IMIDAZOPYRIDINES AND THEIR USE ASTRAZENECA AB (SE) 2007-08-15 EP claimed
US-20050261333-A1 Use of and some novel imidazopyridines ASTRAZENECA A B (SE) 2005-11-24 US claimed
US-7410966-B2 Use of and some novel imidazopyridines ASTRAZENECA AB (SE) 2008-08-12 US disclosed
EP-1539759-B1 NOVEL IMIDAZOPYRIDINES AND THEIR USE ASTRAZENECA AB (SE) 2007-08-15 EP disclosed
US-20050261333-A1 Use of and some novel imidazopyridines ASTRAZENECA A B (SE) 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261333-A1 Use of and some novel imidazopyridines ITK, CSNK1A1, RPS6KA1 ALDH1A1 1489/4885KMT2A 2697/4885DNM1 3922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.